TD Cowen Issues Pessimistic Forecast for Thermo Fisher Scientific (NYSE:TMO) Stock Price

Thermo Fisher Scientific (NYSE:TMO) had its price target reduced by equities research analysts at TD Cowen from $696.00 to $683.00 in a report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. TD Cowen’s price target would indicate a potential upside of 18.47% from the company’s current price.

A number of other equities research analysts also recently commented on the company. UBS Group reaffirmed a “neutral” rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday. Wells Fargo & Company lifted their price objective on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a research note on Sunday, December 7th. Citigroup restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Friday. Finally, Barclays increased their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $631.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $15.65 during midday trading on Friday, reaching $576.51. The company had a trading volume of 1,412,910 shares, compared to its average volume of 2,579,327. The stock has a market cap of $216.60 billion, a P/E ratio of 33.31, a P/E/G ratio of 3.99 and a beta of 0.91. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific has a 1 year low of $385.46 and a 1 year high of $643.99. The business’s 50-day simple moving average is $594.14 and its 200 day simple moving average is $536.01.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.45 by $0.12. The firm had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the firm earned $6.10 EPS. On average, analysts forecast that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 124,517 shares of company stock worth $72,363,568 in the last ninety days. 0.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of large investors have recently modified their holdings of TMO. SOL Capital Management CO lifted its stake in shares of Thermo Fisher Scientific by 9.6% in the fourth quarter. SOL Capital Management CO now owns 1,710 shares of the medical research company’s stock worth $991,000 after buying an additional 150 shares in the last quarter. Carrera Capital Advisors boosted its holdings in shares of Thermo Fisher Scientific by 14.2% during the 4th quarter. Carrera Capital Advisors now owns 779 shares of the medical research company’s stock worth $452,000 after purchasing an additional 97 shares during the last quarter. Westhampton Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 1.2% in the fourth quarter. Westhampton Capital LLC now owns 2,488 shares of the medical research company’s stock valued at $1,442,000 after purchasing an additional 30 shares during the last quarter. Vest Financial LLC boosted its stake in Thermo Fisher Scientific by 25.8% during the fourth quarter. Vest Financial LLC now owns 6,918 shares of the medical research company’s stock worth $4,009,000 after buying an additional 1,419 shares during the last quarter. Finally, KTF Investments LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $527,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Revenue $12.21B (+7% YoY) and adjusted EPS $6.57 (beat), driven by life?sciences tools and pharma services strength; reinforces ongoing demand in drug development markets. Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Bullish analyst commentary and target revisions — Some analysts reaffirm Buy ratings and highlight resilient organic growth and stabilizing end markets; one note sets a $668 target citing margin resilience and competitive positioning. Thermo Fisher: The Market Is Missing The Point, This Pullback Is A Buy (Rating Update)
• Positive Sentiment: Analyst Buy maintained — Firms such as William Blair kept bullish ratings, pointing to resilient organic growth and improving end?market signals. Thermo Fisher Scientific: Resilient Organic Growth and Stabilizing End Markets Support Sustained Buy Rating
• Neutral Sentiment: Potential acquisition upside — Management disclosed how the Clario transaction could add to EPS; this represents a possible future tailwind but timing and integration impact remain uncertain. Thermo Fisher Scientific Discloses How Much Clario Deal Could Add To Its EPS
• Neutral Sentiment: Earnings presentation available — Full call slides and transcript outline segment performance, product trends and cost/margin assumptions for FY2026; useful for modeling but not headline?moving by itself. Thermo Fisher Scientific Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Cautious FY2026 outlook and margin commentary weighed on the stock — Company guided revenue $46.3B–$47.2B (?4–6% growth) and EPS $24.22–$24.80; the EPS/revenue ranges sit roughly in line with or slightly around consensus and management signaled margin pressure, prompting investor concern despite the beat. Thermo Fisher stock slides on cautious profit guidance

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.